Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

Next Previous
Trial Profile

Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alemtuzumab (Primary) ; Alemtuzumab (Primary) ; Dexamethasone (Primary) ; Etoposide (Primary) ; Methotrexate (Primary) ; Tocilizumab (Primary)
  • Indications Haemophagocytic lymphohistiocytosis
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 25 Jan 2023 Status changed from active, no longer recruiting to completed.
  • 22 Sep 2021 Planned End Date changed from 28 Sep 2020 to 30 Sep 2022.
  • 22 Sep 2021 Planned primary completion date changed from 28 Sep 2020 to 30 Sep 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top